45 SIDNEY STREET, CAMBRIDGE, MA
Contingent Value Rights Agreement
Shareholder votes
To Acquire, Expanding Portfolio in Rare Immunological Disease and Adding Early-Stage Pipeline in Immunology
Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Annual Report to Security Holders
Earnings Release
Investor Presentation
Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Q1
FY 2023
Q3
Q2
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
S-8 POS